<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909090</url>
  </required_header>
  <id_info>
    <org_study_id>UGA-2009-10141-1</org_study_id>
    <nct_id>NCT00909090</nct_id>
  </id_info>
  <brief_title>Macular Pigment and Glare Disability</brief_title>
  <acronym>MP-GD</acronym>
  <official_title>Effects of Lutein and Zeaxanthin Upon MPOD and Its Effects Upon Glare Disability, Photostress Recovery, and Contrast Enhancement in Healthy Subjects: A Randomized, Double-blind Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Georgia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

      I. To measure MP optical density (MPOD) in two groups (experimental and placebo) of 50
      subjects each (N = 100), during an Lutein + Zeaxanthin supplementation period of 12 months.

      II. To test the hypothesis that increases in MP (via 12 mg daily Lutein + Zeaxanthin
      supplementation) will result in significantly improved visual performance under disability
      glare conditions.

      III. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will
      result in significantly reduced photostress recovery times.

      IV. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will
      result in improved contrast enhancement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following measurements will be taken, before and after supplementation with lutein and
      zeaxanthin:

      Macular pigment optical density (MPOD) Visual performance under glare conditions Photostress
      recovery times chromatic contrast sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arms: nutritional supplement vs. placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular Pigment Optical Density</measure>
    <time_frame>every three months for one year; 12-month measure reported.</time_frame>
    <description>optical density of macular pigment layer of the neural retina at 30-minutes of retinal eccentricity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glare Disability</measure>
    <time_frame>12-month data point only</time_frame>
    <description>light energy needed to obscure or veil a visual target; calculated as log-relative energy, which is the physical energy needed for the subject to report that the visual target has been veiled, given the intensity of the target, logged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photostress Recovery Time</measure>
    <time_frame>improvement in recovery time; baseline recovery time (sec) minus 12-month recovery time (sec)</time_frame>
    <description>amount of time needed to recover from exposure to a bright light, and to regain sight of a visual target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heterochromatic Contrast Sensitivity</measure>
    <time_frame>12-month data point only</time_frame>
    <description>amount of short-wave light energy necessary to obscure of veil a visual target, calculated as log-relative energy, which is the physical energy needed for the subject to report that the visual target has been veiled, given the intensity of the target, logged.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Vision, Entoptic</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>visually identical placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>12 mg Lutein + Zeaxanthin</intervention_name>
    <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>FloraGlo lutein + OptiSharp zeaxanthin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Visually identical placebo</intervention_name>
    <description>Visually identical placebo, taken once daily for one year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: male or female

          -  Age: 18 - 40 years

          -  BMI: 20-30

          -  No anticipated changes in dieting habits (as relevant to xanthophyll intake).

          -  No anticipated surgical procedures.

          -  Assessed as healthy, based on a pre-study examination including medical history,
             physical examination, and clinical laboratory. The examination will be performed by an
             MD or a Nurse Practitioner.

          -  Willingness and ability to give written informed consent and willingness and ability
             to comply with the study requirements.

          -  Corrected visual acuity (ETDRS): better than 20/60

        Exclusion Criteria:

          -  BMI &lt;20 or &gt;30

          -  Age &lt;18 or &gt;40 years

          -  Smokers

          -  Current or history of relevant diseases (such as AMD)

          -  Corrected visual acuity worse than 20/60

          -  Inability to reliably perform MPOD measurements by heterochromatic flicker photometry
             or any of the other ophthalmic tests of the study.

          -  Any condition likely to interfere with normal gastro-intestinal absorption of
             xanthophylls.

          -  Current use of xanthophyll containing supplements

          -  Use of xanthophyll containing supplements in the past 6 months

          -  Participation in any other study during last 1 month.

          -  Blood donation during the last 3 months.

          -  Known hypersensitivity or allergy to xanthophylls.

          -  Regular intake of medications or supplements, which the principal investigator deems
             likely to confound the study outcomes.

          -  Suspected lack of compliance with any requirements of the study.

          -  Childbearing potential and unwillingness to refrain from acceptable anticonceptive
             measures (not including abstinence).

          -  Current pregnancy or breast feeding

          -  Any relevant abnormalities in the routine laboratory tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male, female, other, non-conforming</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy R Hammond, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vision Sciences Laboratory, UGA</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <results_first_submitted>May 15, 2019</results_first_submitted>
  <results_first_submitted_qc>June 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2020</results_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Georgia</investigator_affiliation>
    <investigator_full_name>Billy R. Hammond</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>macular pigment</keyword>
  <keyword>glare disability</keyword>
  <keyword>lutein</keyword>
  <keyword>photostress</keyword>
  <keyword>chromatic contrast sensitivity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was initiated in May, 2009. The enrollment period was rolling and lasted for 30 months. Enrollment closed in November, 2011. Participants were recruited from the local Athens, Clarke-County community and the University of Georgia student population.</recruitment_details>
      <pre_assignment_details>Key events:
Telephone screening to confirm eligibility Enrollment Randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>12 mg Lutein + Zeaxanthin</title>
          <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
        </group>
        <group group_id="B2">
          <title>Visually Identical Placebo</title>
          <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="4.61"/>
                    <measurement group_id="B2" value="22.7" spread="3.32"/>
                    <measurement group_id="B3" value="23.2" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender</title>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body mass index, computed from height (cm) and weight (kg)</description>
          <units>kg/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.9" spread="2.45"/>
                    <measurement group_id="B2" value="22.8" spread="2.66"/>
                    <measurement group_id="B3" value="22.85" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iris Darkness</title>
          <description>Visual inspection of iris color and comparison to an iris color scale on a computer monitor. Darkest irides score 1-2; Lightest irides score 4-5.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.90" spread="1.31"/>
                    <measurement group_id="B2" value="2.81" spread="1.27"/>
                    <measurement group_id="B3" value="2.86" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Macular Pigment Optical Density</title>
        <description>optical density of macular pigment layer of the neural retina at 30-minutes of retinal eccentricity</description>
        <time_frame>every three months for one year; 12-month measure reported.</time_frame>
        <population>Participants who completed all four measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Luten + Zeaxanthin</title>
            <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Pigment Optical Density</title>
          <description>optical density of macular pigment layer of the neural retina at 30-minutes of retinal eccentricity</description>
          <population>Participants who completed all four measurements</population>
          <units>optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.10"/>
                    <measurement group_id="O2" value="0.42" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glare Disability</title>
        <description>light energy needed to obscure or veil a visual target; calculated as log-relative energy, which is the physical energy needed for the subject to report that the visual target has been veiled, given the intensity of the target, logged.</description>
        <time_frame>12-month data point only</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Glare Disability</title>
          <description>light energy needed to obscure or veil a visual target; calculated as log-relative energy, which is the physical energy needed for the subject to report that the visual target has been veiled, given the intensity of the target, logged.</description>
          <units>log relative energy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.10"/>
                    <measurement group_id="O2" value="1.83" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis compared mean differences between placebo and intervention at the 12-month time point.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Photostress Recovery Time</title>
        <description>amount of time needed to recover from exposure to a bright light, and to regain sight of a visual target</description>
        <time_frame>improvement in recovery time; baseline recovery time (sec) minus 12-month recovery time (sec)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>12 mg Lutein + Zeaxanthin</title>
            <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
          </group>
          <group group_id="O2">
            <title>Visually Identical Placebo</title>
            <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Photostress Recovery Time</title>
          <description>amount of time needed to recover from exposure to a bright light, and to regain sight of a visual target</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="7.5"/>
                    <measurement group_id="O2" value="4.5" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis compared mean change from baseline to 12-month time points.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heterochromatic Contrast Sensitivity</title>
        <description>amount of short-wave light energy necessary to obscure of veil a visual target, calculated as log-relative energy, which is the physical energy needed for the subject to report that the visual target has been veiled, given the intensity of the target, logged.</description>
        <time_frame>12-month data point only</time_frame>
        <group_list>
          <group group_id="O1">
            <title>12 mg Lutein + Zeaxanthin</title>
            <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
          </group>
          <group group_id="O2">
            <title>Visually Identical Placebo</title>
            <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Heterochromatic Contrast Sensitivity</title>
          <description>amount of short-wave light energy necessary to obscure of veil a visual target, calculated as log-relative energy, which is the physical energy needed for the subject to report that the visual target has been veiled, given the intensity of the target, logged.</description>
          <units>log relative energy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.14"/>
                    <measurement group_id="O2" value="1.16" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>analysis conducted on mean change over one year, between groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year</time_frame>
      <desc>Adverse event collection occurred over the phone at one month intervals, and during in-person follow-up visits every three months.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
Intervention: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>visually identical placebo
Placebo: Visually identical placebo, taken once daily for one year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample included only young, healthy adults with acute vision. Because the sample was recruited from the local college student population, there were high rates of attrition (students moving away, forgetting appointments, discontinuing contact)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Billy Hammond, Principal Investigator</name_or_title>
      <organization>University of Georgia</organization>
      <phone>(706) 54204812</phone>
      <email>bhammond@uga.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

